Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 6.18
KALA's Cash-to-Debt is ranked lower than
62% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. KALA: 6.18 )
Ranked among companies with meaningful Cash-to-Debt only.
KALA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.59  Med: 3.72 Max: 6.18
Current: 6.18
0.59
6.18
Debt-to-Equity 0.20
KALA's Debt-to-Equity is ranked lower than
99.99% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. KALA: 0.20 )
Ranked among companies with meaningful Debt-to-Equity only.
KALA' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.17  Med: -0.09 Max: 0.43
Current: 0.2
-0.17
0.43
Debt-to-EBITDA -0.52
KALA's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. KALA: -0.52 )
Ranked among companies with meaningful Debt-to-EBITDA only.
KALA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.62  Med: -0.46 Max: -0.3
Current: -0.52
-0.62
-0.3
Altman Z-Score: 7.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROA % -83.22
KALA's ROA % is ranked lower than
89% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. KALA: -83.22 )
Ranked among companies with meaningful ROA % only.
KALA' s ROA % Range Over the Past 10 Years
Min: -197.47  Med: -159.29 Max: -83.22
Current: -83.22
-197.47
-83.22
ROC (Joel Greenblatt) % -8097.60
KALA's ROC (Joel Greenblatt) % is ranked lower than
80% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. KALA: -8097.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
KALA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8097.6  Med: -3521.73 Max: -2178.59
Current: -8097.6
-8097.6
-2178.59
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» KALA's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with KALA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Kala Pharmaceuticals Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SVRA, NAS:QTRX, NAS:AKAO, LSE:CIR, NAS:SVA, SHSE:600866, SZSE:300705, NAS:MRTX, OSTO:PROB, NAS:KURA, SZSE:002868, SZSE:002873, NAS:CYTK, TSE:7774, LSE:PRTC, NAS:AMAG, XKRX:144510, LSE:HZD, SZSE:002566, XKRX:087010 » details
Traded in other countries:27F.Germany,
Headquarter Location:USA
Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary nanoparticle-based Mucus Penetrating Particles technology, with focus on the treatment of eye diseases.

Kala Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of therapeutics using its proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company's MPPs are selectively-sized nanoparticles and have proprietary coatings. It has applied the MPP technology to create nanosuspensions of loteprednol etabonate, or LE, a corticosteroid designed for ocular applications, resulting in two product candidates in Phase 3 clinical development, KPI-121 1.0% for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.

Ratios

vs
industry
vs
history
PB Ratio 3.79
KALA's PB Ratio is ranked lower than
99.99% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. KALA: 3.79 )
Ranked among companies with meaningful PB Ratio only.
KALA' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 21.45
Current: 3.79
0
21.45
EV-to-EBIT -7.21
KALA's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. KALA: -7.21 )
Ranked among companies with meaningful EV-to-EBIT only.
KALA' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.16  Med: 0 Max: 0
Current: -7.21
-31.16
0
EV-to-EBITDA -7.26
KALA's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. KALA: -7.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
KALA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.48  Med: 0 Max: 0
Current: -7.26
-31.48
0
Current Ratio 10.99
KALA's Current Ratio is ranked higher than
74% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. KALA: 10.99 )
Ranked among companies with meaningful Current Ratio only.
KALA' s Current Ratio Range Over the Past 10 Years
Min: 1.38  Med: 5.42 Max: 10.99
Current: 10.99
1.38
10.99
Quick Ratio 10.99
KALA's Quick Ratio is ranked higher than
75% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. KALA: 10.99 )
Ranked among companies with meaningful Quick Ratio only.
KALA' s Quick Ratio Range Over the Past 10 Years
Min: 1.38  Med: 5.42 Max: 10.99
Current: 10.99
1.38
10.99

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.87
KALA's Price-to-Net-Cash is ranked lower than
99.99% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. KALA: 3.87 )
Ranked among companies with meaningful Price-to-Net-Cash only.
KALA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.87  Med: 5.76 Max: 5.76
Current: 3.87
3.87
5.76
Price-to-Net-Current-Asset-Value 3.83
KALA's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. KALA: 3.83 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
KALA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.83  Med: 5.7 Max: 5.7
Current: 3.83
3.83
5.7
Price-to-Tangible-Book 3.80
KALA's Price-to-Tangible-Book is ranked lower than
99.99% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. KALA: 3.80 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
KALA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.8  Med: 5.66 Max: 5.66
Current: 3.8
3.8
5.66
Earnings Yield (Greenblatt) % -13.86
KALA's Earnings Yield (Greenblatt) % is ranked higher than
54% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. KALA: -13.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KALA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19.65  Med: 0 Max: 0
Current: -13.86
-19.65
0

More Statistics

EPS (TTM) $ -2.43
Short Percentage of Float5.40%
52-Week Range $11.81 - 26.75
Shares Outstanding (Mil)24.52

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

» More Articles for KALA

Headlines

Articles On GuruFocus.com

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}